Optimised treatment for pre-existing Diabetic Macular oEdema during CATaract surgery – a randomised controlled trial (ODMECAT)

Chinese University of Hong Kong0 个研究点目标入组 92 人开始时间: 2021年1月25日最近更新: 2021年2月8日

适应症

试验速览

暂无简介。

•1. History of intravitreal injection of anti-Vascular Endothelial Growth Factor (anti-VEGF) within 1 month, steroids within 3 months, or macular focal/grid laser within 3 months, prior to cataract surgery
•2. Macular oedema from causes other than diabetic maculopathy
•3. Proliferative diabetic retinopathy requiring treatment, media opacities which affect fundus examination or Optical Coherence Tomography (OCT) measurements at baseline, or known significant macular ischemia demonstrated on fluorescein angiography or OCTA
•4. Pre-existing glaucoma at the time of enrolment or previous history of steroid response (Intraocular Pressure (IOP) elevation >35 mmHg following steroid treatment)
•5. Ocular disorders in the study eye at the time of enrollment that may confound interpretation of study results and compromise visual acuity (including retinal detachment, age-related macular degeneration, pathologic myopia, lamellar macular hole, and epiretinal membrane of the macula)
•6. History of hypersensitivity to any intravitreal drugs
•7. History of stroke or myocardial infarction within the 6 months prior to the screening visit
•8. Pregnant or lactating

发起方